Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 2.8M | 15.3% |
| Gross Profit | 2.1M | 34.8% |
| Cost of Revenue | 620,000 | 22.9% |
| Operating expense | 14M | 29.2% |
| Net Income | -11M | 35.2% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 161M | 7.5% |
| Total Liabilities | 27M | 15% |
| Total Equity | 134M | 5.8% |
| Shares Outstanding | 71M | 0.1% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | -12M | 40.8% |
| Cash from investing | -670,000 | 104% |
| Cash from financing | -11,000 | 80% |
EPS
Financial Highlights for Aclaris Therapeutics in Q2 '24
Aclaris Therapeutics reported a revenue of 2.8M, which is a 15.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.1M, marking a 34.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 620,000, a -22.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 14M, showing a -29.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -11M, showing a 35.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
It was a positive quarter for Aclaris Therapeutics with growth in revenue, gross profit, and net income.